How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,170 results for

Thrombocytopenia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Immune thrombocytopenia

Immune thrombocytopenia Immune thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Immune thrombocytopenia Last reviewed: February 2019 Last updated: March 2019 Summary Immune thrombocytopenia (ITP), also known as immune thrombocytopenic purpura, is defined as an autoimmune haematological disorder characterised by isolated thrombocytopenia in the absence of an identifiable cause. Typically found (...) in children often with a preceding viral illness and an abrupt onset. There is a female preponderance among adults, who may present with thrombocytopenia with or without bleeding. Petechiae occur primarily on the lower limbs, but can appear anywhere on the body (including mucosal membranes), particularly if thrombocytopenia is severe. Bruising is common. Mucosal bleeding may also occur in more severe cases. Intracranial bleeding is reported in less than 1% of adults and less than 0.5% of children. Full

2019 BMJ Best Practice

2. Lusutrombopag - to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease

Lusutrombopag - to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/889817/2018 (...) EMEA/H/C/004720 Lusutrombopag Shionogi (lusutrombopag) An overview of Lusutrombopag Shionogi and why it is authorised in the EU What is Lusutrombopag Shionogi and what is it used for? Lusutrombopag Shionogi is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding. The medicine is for use

2019 European Medicines Agency - EPARs

3. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT)

Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) - Regan - - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term RCOG Scientific Impact Paper Free Access Prenatal Management of Pregnancies (...) at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Scientific Impact Paper No. 61 on behalf of Corresponding Author E-mail address: Correspondence : Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Email: on behalf of Corresponding Author E-mail address: Correspondence : Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Email: First published: 09 April 2019 Give access Share full text

2019 Royal College of Obstetricians and Gynaecologists

11. Assessment of thrombocytopenia

Assessment of thrombocytopenia Assessment of thrombocytopenia - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of thrombocytopenia Last reviewed: February 2019 Last updated: June 2018 Summary Thrombocytopenia is defined as a low circulating platelet count (<150,000 per microlitre). Platelet life span is normally approximately 5 days, with continual renewal. True thrombocytopenia results from either (...) a reduced production of platelets in the bone marrow, increased clearance, or sequestering of platelets in the spleen. Epidemiology The causes of thrombocytopenia are diverse, making epidemiological generalisations difficult. However, immune thrombocytopenia (ITP) is typically an illness of young women. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186. http

2018 BMJ Best Practice

12. Heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia Heparin-induced thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Heparin-induced thrombocytopenia Last reviewed: February 2019 Last updated: May 2018 Summary A severe drug reaction to heparin that can lead to life- and limb-threatening venous and/or arterial thromboembolism. Diagnosis requires the combination of a compatible clinical picture and laboratory confirmation (...) of the presence of heparin-dependent platelet-activating HIT antibodies. Neither discontinuation of heparin alone nor initiation of a vitamin K antagonist alone (e.g., warfarin) is sufficient to stop the development of thrombosis in a patient with acute HIT. If clinical suspicion for HIT is at least moderate, all sources of heparin (including low molecular weight heparin) must be discontinued and initiation of treatment with a non-heparin anticoagulant considered. Definition Heparin-induced thrombocytopenia

2018 BMJ Best Practice

13. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. (PubMed)

Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. People with a low platelet count (thrombocytopenia) often require lumbar punctures or an epidural anaesthetic. Lumbar punctures can be diagnostic (haematological malignancies, subarachnoid haematoma, meningitis) or therapeutic (spinal anaesthetic, administration of chemotherapy). Epidural catheters are placed for administration of epidural (...) anaesthetic. Current practice in many countries is to correct thrombocytopenia with platelet transfusions prior to lumbar punctures and epidural anaesthesia, in order to mitigate the risk of serious procedure-related bleeding. However, the platelet count threshold recommended prior to these procedures varies significantly from country to country. This indicates significant uncertainty among clinicians regarding the correct management of these patients. The risk of bleeding appears to be low

Full Text available with Trip Pro

2018 Cochrane

14. Diagnosis and management of typical, newly diagnosed primary immune thrombocytopenia (ITP) of childhood

Diagnosis and management of typical, newly diagnosed primary immune thrombocytopenia (ITP) of childhood This practice point applies to children aged 90 days through 17 years who have typical, newly diagnosed primary immune thrombocytopenia (ITP).  Current recommendations on management and information from recent studies are summarized with the goal of decreasing variable practice among providers and improving patient-centred care. Options for initially managing young patients (...) . Keywords: Intracranial hemorrhage (ICH); Immune thrombocytopenia (ITP); Intravenous immunoglobulin (IVIG); Shared decision-making (SDM)

2018 Canadian Paediatric Society

15. The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper

The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper - Hill - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term (...) The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper Department of Haematology, Leeds Teaching Hospitals, Leeds, UK Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK Faculty

Full Text available with Trip Pro

2019 British Committee for Standards in Haematology

16. Thrombocytopenia in Pregnancy

Thrombocytopenia in Pregnancy Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

17. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. (PubMed)

Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Chemotherapy-induced thrombocytopenia (CIT) is defined as a peripheral platelet count less than 100×109/L, with or without bleeding in cancer patients receiving myelosuppressive chemotherapy. CIT is a significant medical problem during chemotherapy, and it carries the risk of sub-optimal overall survival and bleeding. Alternative interventions to platelet (...) transfusion are limited. Different stages of preclinical and clinical studies have examined the thrombopoietin receptor agonists (TPO-RAs) for CIT in patients with solid tumours.To assess the effects of TPO-RAs to prevent and treat CIT in patients with solid tumours:(1) to prevent CIT in patients without thrombocytopenia before chemotherapy, (2) to prevent recurrence of CIT, and (3) to treat CIT in patients with thrombocytopenia during chemotherapy.We searched the Cochrane Central Register of Controlled

Full Text available with Trip Pro

2017 Cochrane

18. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. (PubMed)

Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction presenting as a prothrombotic disorder related to antibody-mediated platelet activation. It is a paradoxical immune reaction resulting in thrombin generation in vivo, which leads to a hypercoagulable state and the potential to initiate venous or arterial thrombosis. A number of factors are thought (...) of bleeding have been described with LMWH and UFH. The decision as to which of these two preparations of heparin to use may thus be influenced by harmful effects such as HIT. We therefore sought to determine the relative impact of UFH and LMWH on HIT in postoperative patients receiving thromboembolism prophylaxis. This is an update of a review first published in 2012.The objective of this review was to compare the incidence of heparin-induced thrombocytopenia (HIT) and HIT complicated by venous

Full Text available with Trip Pro

2017 Cochrane

19. Fostamatinib (Tavalisse) - To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP)

Fostamatinib (Tavalisse) - To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP) Drug Approval Package: TAVALISSE (fostamatinib disodium hexahydrate) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TAVALISSE (fostamatinib disodium hexahydrate) Company: Rigel Pharmaceuticals, Inc. Application Number: 209299 Approval Date: 04/17/2018 Persons with disabilities having problems accessing the PDF files below

2018 FDA - Drug Approval Package

20. Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness

Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness | CADTH.ca Find the information you need Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Published on: April 19, 2017 Project Number: RB1085-000 Product Line (...) : Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness the use of fondaparinux to treat patients with type II heparin-induced thrombocytopenia? What is the clinical effectiveness the use of direct oral anticoagulants to treat patients with type II heparin-induced thrombocytopenia? Key Message One systematic review and eight non-randomized studies were identified regarding the clinical effectiveness of fondaparinux and/or direct oral

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>